Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
RefluxRaft is a consumer healthcare company that develops and markets alginate-based treatments for acid reflux and laryngopharyngeal reflux (LPR). Its primary product uses a naturally derived seaweed extract to form a physical barrier, or "raft," that floats on top of stomach contents to prevent the reflux of acid and pepsin into the esophagus and throat. This mechanical approach offers a drug-free alternative to systemic medications like proton pump inhibitors (PPIs) and H2 blockers. The company focuses on providing fast-acting relief for patients suffering from chronic heartburn and throat-related reflux symptoms, particularly during post-meal and nighttime periods. RefluxRaft's formulations are designed to be safe for long-term use and are often recommended by specialists in otolaryngology and gastroenterology.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on RefluxRaft.